The transcription factor IRF4 (interferon regulatory factor 4) is required during an immune response for lymphocyte activation and the generation of immunoglobulin-secreting plasma cells [1] [2] [3] . Multiple myeloma, a malignancy of plasma cells, has a complex molecular aetiology with several subgroups defined by gene expression profiling and recurrent chromosomal translocations 4,5 . Moreover, the malignant clone can sustain multiple oncogenic lesions, accumulating genetic damage as the disease progresses 6,7 . Current therapies for myeloma can extend survival but are not curative 8, 9 . Hence, new therapeutic strategies are needed that target molecular pathways shared by all subtypes of myeloma. Here we show, using a loss-of-function, RNA-interference-based genetic screen, that IRF4 inhibition is toxic to myeloma cell lines, regardless of transforming oncogenic mechanism. Gene expression profiling and genome-wide chromatin immunoprecipitation analysis uncovered an extensive network of IRF4 target genes and identified MYC as a direct target of IRF4 in activated B cells and myeloma. Unexpectedly, IRF4 was itself a direct target of MYC transactivation, generating an autoregulatory circuit in myeloma cells. Although IRF4 is not genetically altered in most myelomas, they are nonetheless addicted to an aberrant IRF4 regulatory network that fuses the gene expression programmes of normal plasma cells and activated B cells.
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Recently, we developed a genetic method to identify therapeutic targets in cancer in which small hairpin RNAs (shRNAs) that mediate RNA interference are screened for their ability to block cancer cell proliferation and/or survival 10 . Here we report the results of such an 'Achilles' heel' screen in multiple myeloma (Supplementary Table 3) . We used myeloma cell lines from three molecular subtypes: KMS12 (CCND1 translocation), H929 (FGFR3-MMSET translocation) and SKMM1 (MAFB, IRF4 translocations). Myeloma cells that received an shRNA targeting the coding region of IRF4 were depleted from cultures by 2-8-fold (Fig. 1a) . Lymphoma cell lines were largely unaffected by IRF4 knockdown, with the exception of OCI-Ly3, an activated B-cell-like diffuse large B cell lymphoma line that expresses IRF4 highly 11 . We next identified two further shRNAs against IRF4 that were toxic to myeloma cell lines, one of which was directed against the IRF4 39 untranslated region (UTR; Supplementary Fig.  1 ). The toxicity of this shRNA was associated with a 50%-75% decrease in IRF4 messenger RNA and protein ( Supplementary Fig.  2a-c) . Cell death occurred within 3 days, as measured by an increase in sub-G1 DNA content; there was, however, no effect on the cell cycle ( Supplementary Fig. 2d-g ). Expression of a complementary DNA containing only the coding region of IRF4 was able to rescue myeloma cells from the toxicity of the 39 UTR-directed IRF4 shRNA, confirming that the toxicity of this shRNA was specific (Fig. 1b) .
The knockdown of IRF4 killed ten myeloma cell lines, but had a minimal effect on five lymphoma cell lines (Fig. 1c) . These myeloma lines bear many of the recurrent genetic aberrations typical of this cancer, including translocations of CCND1, MYC, MAF, MAFB, FGFR3-MMSET, NIK and IRF4, as well as RAS mutations, inactivation of TP53 and CDKN2C, and genetic abnormalities that activate the NF-kB pathway (Supplementary Table 1 ). Resequencing of the IRF4 coding exons in these lines showed that nine had a wild-type sequence and one had a heterozygous mutation in exon 8 resulting in a missense substitution, the functional significance of which is unknown. Moreover, no amplification of the IRF4 locus was detected by array-based comparative genomic hybridization and no translocations involving IRF4 were detected by cytogenetics, with the exception of the previously documented IRF4 translocation in SKMM1 cells (data not shown). Thus, IRF4 dependency spans many myeloma subtypes and does not require genetic abnormalities in the IRF4 locus.
To understand the molecular basis for this dependency, we identified downstream targets of IRF4 by profiling gene expression changes in myeloma lines after induction of IRF4 shRNAs ( Supplementary Fig. 3 ). A total of 308 genes were consistently downregulated after IRF4 knockdown (Supplementary Table 2 ). This list was significantly enriched for genes that are more highly expressed in primary myeloma samples than in normal, mature B cells, on the basis of gene set enrichment analysis 12 of published gene expression profiling data (P 5 0.002; Fig. 2a ) 13 . Thus, IRF4 directs a broad gene expression programme that is characteristic of primary myeloma cells.
We next investigated whether the IRF4 target genes in myeloma are also upregulated in other normal haematopoietic cells that require high IRF4 expression, including plasma cells 3 , mitogenically activated mature B cells 1 and dendritic cells 14 . Human bone-marrowderived plasma cells expressed 22% of the IRF4 target genes at higher levels than mature blood B cells (Fig. 2a ) 13 . Similarly, 25% of the IRF4 targets were more highly expressed in dendritic cells than in monocytes ( Supplementary Fig. 4 ) 15 . Blood B cells activated by anti-IgM crosslinking expressed one-third of the IRF4 target genes more highly than resting B cells (Fig. 2a) .
However, IRF4 regulates a broader set of genes in myeloma than in individual haematopoietic subsets. Roughly one-quarter of the IRF4 target genes in myeloma were upregulated in activated B cells but not plasma cells, including genes known to be important in cellular growth and proliferation, such as MYC (Fig. 2a) . Conversely, onesixth of the myeloma IRF4 target genes were highly expressed in plasma cells but not activated B cells.
To identify direct IRF4 targets, we performed genome-wide chromatin immunoprecipitation using DNA microarrays (ChIP-CHIP) with probes spanning ,10 kb at the 59 end of 17,574 human genes. Specific IRF4 binding to 558 genes was detected in a myeloma cell line (KMS12) but not a lymphoma cell line (OCI-Ly19). Of these, 35 were also IRF4 targets by gene expression profiling, a highly significant overlap (P 5 1.0 3 10 216 , chi-squared; Fig. 2b and Supplementary  Fig. 5 ), and were considered presumptive direct IRF4 targets (Supplementary Table 2 ). Direct binding of IRF4 was confirmed by conventional chromatin immunoprecipitation for 22 genes, leading us to conclude that all 35 genes are probably IRF4 direct targets ( Fig. 2b and data not shown). This list of IRF4 direct targets is a conservative estimate because the ChIP-CHIP arrays interrogate limited regions around each gene. Indeed, direct ChIP experiments demonstrated that two other IRF4 target genes, PRDM1 and SQLE, were directly bound by IRF4 in regions not covered by our ChIP-CHIP analyses ( Supplementary Fig. 5 ). IRF4 bound to the promoter and fourth intron of PRDM1, which encodes BLIMP-1, another important regulator of plasmacytic differentiation ( Supplementary  Fig. 5 ). These observations support the proposal that IRF4 lies genetically upstream of PRDM1 in the regulatory hierarchy of terminal B cell differentiation 3 . Notably, IRF4 bound to its own promoter, supporting a positive feedback mechanism by which plasma cells can maintain high IRF4 expression 3 ( Supplementary Fig. 5 ). A direct IRF4 target of particular interest is MYC given its prominent role in the pathogenesis of myeloma 16 . Knockdown of IRF4 reduced MYC mRNA levels by more than twofold in myeloma cell lines and caused MYC DNA-binding activity to decrease in nuclear extracts of myeloma cells. Conversely, ectopic expression of IRF4 in a lymphoma cell line increased MYC mRNA levels ( Fig. 3a and Supplementary Fig. 6 ). Using ChIP, we surveyed regions of the MYC locus for binding by IRF4 in myeloma cells and detected a peak of binding around 21.6 kb upstream of the MYC start site, coinciding with a region detected by ChIP-CHIP ( Fig. 3b and Supplementary Fig. 7 ). Knockdown of IRF4 expression diminished the amount of IRF4 bound to this region of the MYC promoter BSPRY  CANX  CASP3  CAV1  CCL3  CFLAR  ELL2  KRAS  LDLR  NDRG1  PAM  SLAMF7  SLC3A2*  TIMP2  UAP1  UCK2   AMPD1  APOBEC3B  ATF3  ATF4  C11orf24  CCPG1  CD38  DDIT3  DNAJB9  DUSP5  F12  FKBP11*  GFPT1  HSP90B1  HSPB1  MAN2A1  NFIL3  NR4A1  PABPC4  PBEF1*  PDIA4  PDK1  PIM2  PRDM1  SORT1  SPATS2  SSR1  SUB1  TM9SF4  TNFAIP3  TNFRSF17  TRAM1  TUFT1  TXNDC5  UBE2J1  ZFP36   AHCY*  ATP5D*  CCNC  CD97  CYCS*  CYP51A1  EIF2S2  GARS  GRSF1  HMBS  LDHA*  MARS  MYC  NP*  PAICS*  PGK1  SLC31A1  VDAC1*  XPOT  YARS   ALDOC  AURKA  BCL2  C17orf39  CTH  FADS1  FDFT1  GART  GFOD1  GNG10*  GNPDA1  GOLGA7  GTF2IRD1  HIG2  HIVEP2  HK2*  HMGCR*  IDH1  INSIG1   KTN1  LONP1  ME2  MVK  OSBPL8  PRPF40A  RIN2  RPP30  SC4MOL  SCD  SEPT11  SERF1A  SNX9  SQLE  SRPK1  ST3GAL1  TAGLN2  TBC1D8   BCKDHA  BCL2L2  DNAJC10  FHL1  GAA  GNG7  HDAC5  HSP90AA1  ISG20  ITGA4  LDLRAP1  MPZL1  MXI1*  P4HA1  PIP5K1B  PPP1R2  PPP2R5C  SCC-112  SLC37A4  SLC38A2  SUMO1  TLOC1  UBE2B  UBE2H (Fig. 3c) . In human B cells, phorbol myristate acetate (PMA) and ionomycin treatment induces transcription of IRF4 and MYC (data not shown). Correspondingly, a sharp increase in IRF4 binding to the MYC promoter was detected after 3 and 20 h of PMA and ionomycin activation (Fig. 3d) . Genetic evidence that Myc is an Irf4 target was provided by analysis of mitogenically stimulated wild-type and Irf4-deficient mouse B cells (Fig. 3e) . In Irf4-deficient cells, both Myc and Prdm1 failed to be fully induced by PMA and ionomycin treatment whereas the immediate early gene Fos was normally induced, and a housekeeping gene, Usf2, did not change in expression. Finally, ectopic expression of IRF4 in a lymphoma cell line was able to transactivate a reporter construct in which GFP is under the control of the MYC promoter (Fig. 3f) .
These data provide strong evidence implicating MYC as a direct target gene of IRF4. Accordingly, the list of IRF4 targets was highly enriched for genes that are directly transactivated by MYC [17] [18] [19] (n 5 23; P 5 1 3 10 28 , chi-squared; Supplementary Table 2 and Supplementary Fig. 9 ). These genes encode principal components of glycolysis (LDHA, HK2 and PDK1) and mitochondrial respiration (ATP5D, CYCS), as well as important regulators of cellular senescence (BMI1, TERT). As MYC is a key coordinator of cellular growth, metabolism and proliferation 20 , we examined whether knockdown of MYC expression was toxic to myeloma cells. An shRNA targeting the MYC 39 UTR knocked down MYC expression and DNA binding by ,twofold (Supplementary Fig. 6 ). This shRNA was toxic to both myeloma and lymphoma cell lines but had little effect on the myeloma cell line U266, consistent with its high expression of MYCL1 instead of MYC (Fig. 4a ) 21 . Expression of the MYC coding region was able to rescue cells from the toxicity of the 39 UTRdirected MYC shRNA, confirming its specificity (Fig. 4b) . Thus, loss of MYC expression may contribute to the toxicity of IRF4 shRNAs for myeloma cells.
Using two independent MYC shRNAs, we identified the targets of MYC in myeloma cells. After MYC shRNA induction, the expression levels of many direct MYC targets decreased (Fig. 4c) . The expression of IRF4 also decreased, as did the expression of many IRF4 target genes (Fig. 4c, d ). ChIP demonstrated binding of MYC to a region of the IRF4 first intron in two myeloma cell lines expressing MYC (KMS12 and H929) but not in a cell line with very low MYC expression (U266, Fig. 4e ). Furthermore, we detected MYC binding to IRF4 in mitogenically activated B cells, which express MYC, but not in resting B cells, which do not (Fig. 4f) .
These data show a positive regulatory loop in myeloma cells in which IRF4 and MYC mutually reinforce the expression of each other (Fig. 5a ). In keeping with this model, myeloma patient samples express both MYC and IRF4 mRNA more highly than normal plasma cells (P 5 5.1 3 10 27 for IRF4; Fig. 4g ). Moreover, MYC and IRF4 mRNA levels showed significant positive correlation across 451 primary myeloma samples 4 (r 5 0.24, P 5 2.5 3 10 27 , Supplementary Fig. 7 ). This moderate correlation was notable because IRF4 is probably only one of many factors regulating MYC transcription in myelomas 22 . Although the MYC locus in myeloma is often amplified and inserted at ectopic genomic locations, especially within and near the immunoglobulin loci 16 , the MYC breakpoints in these chromosomal rearrangements are many kilobases from the MYC transcriptional start site and thus preserve the IRF4 binding region. Our data suggest that the oncogenic activation of MYC in myeloma upregulates IRF4, which in turn drives expression of MYC and other IRF4 target genes (Fig. 5a) .
In some respects, the dependency of myeloma cells on IRF4 is reminiscent of the function of 'lineage survival' oncogenes 23 . These genes are primarily transcription factors that provide essential functions in a particular cellular lineage but are also dysregulated in cancers derived from that lineage. IRF4 differs from lineage survival oncogenes in two respects. First, many lineage survival oncogenes are altered by mutations or chromosomal structural alterations whereas the IRF4 locus seems to be unaltered in most myelomas. Second, the regulatory network that IRF4 controls in myeloma is decidedly abnormal, not merely reflecting the genetic programme of normal plasma cells but also borrowing from the genetic programme of antigen-stimulated mature B cells (Figs 2a and 5b) . This transcriptional promiscuity is exemplified by the direct IRF4 targets MYC, SCD, SQLE, CCNC and CDK6, which are not highly expressed in normal plasma cells but are upregulated in mature B cells on antigen receptor signalling (Figs 2a and 5b) . Thus, myelomas have broadened the genetic repertoire of IRF4, perhaps due to epigenetic alterations that allow IRF4 access to loci that are normally silenced in plasma cells. Hence, the dependency of myeloma on IRF4 may be best described as 'non-oncogene addiction'; that is, the aberrant function of a normal cellular protein that is required for cancer cell proliferation or survival 24 . The direct targets of IRF4 show that it is a master regulator influencing metabolic control, membrane biogenesis, cell cycle progression, cell death, transcriptional regulation and plasmacytic differentiation (Fig. 5b) . Given this pleiotropic programme, we believe that loss of IRF4 in a myeloma cell results in 'death by a thousand cuts'. For example, several important cell-cycle regulators are IRF4 targets, in keeping with its role in lymphocyte activation 1 , including STAG2, CDK6 and MYC. STAG2 encodes a component of the cohesin complex crucially involved in the segregation of chromosomes during mitosis 25 . Two different shRNAs targeting STAG2 were toxic for both a myeloma and a lymphoma cell line ( Supplementary Fig. 8 ), as were shRNAs targeting MYC (Fig. 4a) . Similarly, myeloma cells were specifically killed by two different shRNAs targeting SUB1, an IRF4 direct target which encodes a transcriptional coactivator 26 . It seems probable, therefore, that decreased expression of each of these IRF4 direct targets contributes to IRF4 shRNA toxicity. A prominent role for IRF4 in regulating membrane biogenesis was indicated by the many enzymes and regulators of sterol and lipid synthesis under its control ( Supplementary Fig. 9 ), including SQLE and SCD, which encode rate-limiting enzymes in these pathways. Furthermore, the IRF4 target gene set was strikingly enriched for genes encoding components of glucose metabolism and ATP production, many of which are targets of MYC (Supplementary Fig. 9 ). As a result it is plausible that metabolic collapse also contributes to cell death caused by IRF4 deprivation. GARS  ATF4  MYC  DDIT3  ALDOC  JUP  VEGFA  IRF4  SCD  EIF2S2  BCL2  PTPN6  PGK1  EIF3S6*  GART  TCEA1  BCKDHA  HK2  RAD21  NDRG1  BMP6  DDR2  CYCS*  SRPK1  P4HA1  SLC2A1  CDK6  SUMO1  CCPG1  PAICS*  PPP2R5C  ADAM9  FADS1  FYN  PBEF1*  STRBP  NP*  IDH1  AURKA  NR4A1  ACP1*  UAP1  STAG2  TCERG1  PAIP2  UBE2H  PTPN22  GNG10*   SLC3A2  SLC7A5  CEBPB  MYC  IARS  NPM1  LTA4H  NME1  EIF3S6  TOMM20  PCCB  GTPBP9  ABLIM1  APRT  CYCS  CSE1L  AK2  IDH3B  RAD54L  TXNRD1  PAICS  ADSL  GSPT1  PBEF1  NP  SRP72  ACP1  BNIP3  BUB1  BCLAF1  JOSD3  PGAM1 Our data demonstrate that myelomas are addicted to an abnormal regulatory network controlled by IRF4, irrespective of their molecular subtype and underlying oncogenic abnormalities. Hence, IRF4 emerges as a master regulator of an aberrant and malignancy-specific gene expression programme relevant to all molecular subtypes of this cancer. Because mice lacking one allele of Irf4 are phenotypically normal 1 and as a ,50% knockdown of IRF4 mRNA and protein was sufficient to kill myeloma cell lines, a therapeutic window may exist in which IRF4-directed therapy might kill myeloma cells while sparing normal cells. Alhough transcription factors have been considered intractable therapeutic targets, recent successful targeting of p53 (ref. 27 ) and BCL-6 (ref. 28) provides hope that IRF4 can be exploited as an Achilles' heel of multiple myeloma.
METHODS SUMMARY
Lines were engineered to express the ecotropic retroviral receptor and the bacterial tetracycline repressor as described 10 . The retroviral constructs for shRNA expression and the design of shRNA library sequences have been described 10 ; in some vectors, the puromycin selectable marker (puro) was replaced by a fusion between puro and green fluorescent protein (GFP) for tracking by flow cytometry. Doxycyline (20 ng ml 21 ) was used for shRNA induction. IRF4 and MYC were expressed using retroviral vectors as described 3 . Primary human resting blood B cells were purified by magnetic separation (CD19 1 beads, Miltenyi) and grown at 2 million cells ml 21 in IMDM containing 10% fetal bovine serum; primary mouse splenic, resting B cells were purified by magnetic separation (B cell kit, Miltenyi) and grown at 2 million cells ml 21 in RPMI plus 10% fetal bovine serum. Lymphocytes were activated with PMA (40 ng ml 21 ) and ionomycin (2 mM). Gene expression profiling was performed using Agilent 4 3 44K or Lymphochip 29 microarrays. ChiP-CHIP experiments were performed using Agilent Human Promoter Set microarrays. 
